EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies

Von Diabetes zu Tumorwachstum: die Auswirkungen blutzuckersenkender Therapien

R Modica, A Liccardi, V Zamponi, A Gagliardi, A Nistor, G Veroi, A Arecco, A Faggiano, A Colao

Endocrine · 04.05.2026 · 91 (1)

DOI: 10.1007/s12020-026-04644-1 ↗

Auf einen Blick

Narrative Übersichtsarbeit zu mechanistischen Zusammenhängen und klinischer Evidenz zu Krebsrisiken unter Antidiabetika. Insgesamt zeigt die randomisierte Evidenz überwiegend neutrale Effekte auf die Krebsinzidenz.

Fragestellung

Welche Hinweise gibt es zur onkologischen Sicherheit blutzuckersenkender Therapien bei Diabetes?

Methode

Narrative Review; gezielte Suchen in PubMed/MEDLINE und Embase plus Handsuche. Mechanistische Daten getrennt von klinischer Evidenz; priorisiert wurden randomisierte Studien und kardiovaskuläre Outcome-Studien.

Ergebnisse

Metformin, Thiazolidindione, GLP-1-Rezeptoragonisten, duale GLP-1/GIP-Agonisten, SGLT2-Inhibitoren und Insulin zeigten überwiegend keine Erhöhung des Krebsrisikos; teils wurden protektive Signale beschrieben.

Einschränkungen

Nicht präspezifizierte Endpunkte, begrenzte onkologische Adjudizierung, kurze Nachbeobachtung, wenige organspezifische Ereignisse und mögliche competing-risk-Effekte.

Schlussfolgerung der Autor:innen

Die randomisierte Evidenz spricht überwiegend für einen neutralen Effekt antidiabetischer Therapien auf die Krebsinzidenz; einige Substanzen zeigen möglicherweise protektive Signale.

Kernaussagen

  • Randomisierte Evidenz: überwiegend neutraler Effekt auf Krebsinzidenz
  • Für einzelne Substanzen wurden mögliche protektive Signale beschrieben
  • Limitiert durch kurze Nachbeobachtung und wenige organspezifische Ereignisse

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine, online erschienen am 04.05.2026. Verfasst von R Modica und 8 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. roberta.…. Hauptthemen laut MEDLINE: Neoplasms, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Napoli Federico II.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Diabetes mellitus and cancer are two expanding global health burdens that share upstream determinants, yet diabetes may also contribute to malignancy risk through hyperglycaemia/AGE-related stress, insulin resistance with compensatory hyperinsulinaemia, obesity-related inflammation, and tumour microenvironment modulation. This narrative review synthesizes mechanistic plausibility and critically appraises the highest-level clinical evidence on the oncologic safety signals of glucose-lowering therapies, with a focus on cancer incidence captured within randomized diabetes trials. Methods argeted searches of PubMed/MEDLINE and Embase were complemented by manual reference screening. Mechanistic and translational data were summarized separately from clinical evidence. For each drug class, we prioritized pivotal randomized controlled trials and cardiovascular outcome trials (phase 3–4, large, practice-defining), extracting malignancy reporting collected as adverse events/serious adverse events or events of special interest. When randomized evidence was limited, high-quality meta-analyses and selected real-world studies were used for context, clearly distinguished from prespecified randomized evidence.

Results

Metformin shows a predominantly neutral effect on cancer incidence, with possible indirect protective signals but no trials specifically designed to assess chemoprevention. Thiazolidinediones demonstrate an overall neutral malignancy profile, with early concerns regarding bladder cancer not confirmed in adjudicated analyses. GLP-1 receptor agonists and dual GLP-1/GIP agonists consistently show no increase in overall or site-specific cancer risk, with emerging signals of reduced obesity-related malignancies. SGLT2 inhibitors display class-wide oncologic neutrality, with heterogeneous and inconclusive drug-specific patterns in meta-analyses. Randomized evidence confirms that insulin, including long-acting analogues, does not increase cancer risk.

Conclusion

Current randomized evidence supports a predominantly neutral effect of antidiabetic therapies on cancer incidence, with some agents showing promising signals of protection. This interpretation is constrained by non-prespecified endpoints, limited oncologic adjudication, short follow-up relative to tumour latency, low site-specific event counts, and potential competing-risk effects. Dedicated long-term trials and registry-linkage strategies with cancer-focused endpoints are needed to clarify whether any therapies confer true protection or warrant targeted monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHypoglycemic AgentsDiabetes Mellitus, Type 2HumansPPAR-gamma AgonistsMetformin

Stichwörter der Autor:innen

antidiabetics drugscancerdiabetesrisk factortumors

Substanzen

Hypoglycemic AgentsPPAR-gamma AgonistsMetformin

Autor:innen und Institutionen

  • Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. roberta.modica@unina.it.
  • Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
  • Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Department of Experimental Medicine, Section of Medical Physiopathology, Nutrition Science and Endocrinology, Sapienza University, Rome, Italy.
  • Department of Endocrinology, San Camillo-Forlanini Hospital, Rome, 00152, Italy.
  • Endocrinology Unit, Department of Internal Medicine and Medical Specialties, School of Medical and Pharmaceutical Sciences, University of Genova, Genova, 16132, Italy.

Förderung

  • Università degli Studi di Napoli Federico II

Zitieren

APA

Modica, R., Liccardi, A., Zamponi, V., Gagliardi, A., Nistor, A., Veroi, G., Arecco, A., Faggiano, A., & Colao, A. (2026). From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies. Endocrine, 91(1). https://doi.org/10.1007/s12020-026-04644-1

Vancouver

Modica R, Liccardi A, Zamponi V, Gagliardi A, Nistor A, Veroi G, et al. From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies. Endocrine. 2026;91(1). doi:10.1007/s12020-026-04644-1

BibTeX
@article{Modica2026,
  author = {Modica, R and Liccardi, A and Zamponi, V and Gagliardi, A and Nistor, A and Veroi, G and Arecco, A and Faggiano, A and Colao, A},
  title = {From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies},
  journal = {Endocrine},
  year = {2026},
  volume = {91},
  number = {1},
  doi = {10.1007/s12020-026-04644-1}
}
Kostenlos starten →